Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: BigKahuna, BooDog, TOB, sox040713, Astavakra, TheHound
Search This Board:
Last Post: 8/27/2016 10:29:38 PM - Followers: 707 - Board type: Free - Posts Today: 0

Cellceutix Corporation (CTIX)
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at 


Ongoing Human Trials:
Product Pipeline:


Recent News and Press Releases:

Seeking Alpha focus articles on CTIX:

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f

Share Structure:  See SEC filing link above for current share structure

Cellceutix IP - Patent Filings:



Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:

Following is a WEEKLY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTIX News: Insider Financial Publishes New Research On Three Promising Biotechs 07/16/2016 08:00:00 AM
CTIX News: Securities Registration: Employee Benefit Plan (s-8) 07/15/2016 04:52:11 PM
CTIX News: Securities Registration: Employee Benefit Plan (s-8) 07/15/2016 04:50:06 PM
CTIX News: Current Report Filing (8-k) 07/14/2016 08:11:43 AM
CTIX News: Statement of Changes in Beneficial Ownership (4) 07/11/2016 01:03:04 PM
#156616  Sticky Note Interview With New Cellceutix President Dr A Bertolino BigKahuna 08/11/16 11:49:13 PM
#156603  Sticky Note CTIX Interviews, Potential Catalysts and Past Milestones sox040713 08/11/16 06:13:05 PM
#156101  Sticky Note Cellceutix Prepares Phase 2a Ovarian Cancer Trial of DaubersUP 08/03/16 09:32:39 AM
#155690  Sticky Note Risk vs Volatility - I've been quietly watching BioHedge 07/26/16 12:34:09 AM
#155456  Sticky Note Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For wild4ctix 07/21/16 07:15:58 AM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#157610   For you and a few others, I hope so............ etradeedge 08/27/16 10:29:38 PM
#157609   We deserve a run to $2+ tombrady12nh 08/27/16 08:09:46 PM
#157608   Scottsmith New test results could be soon. Echo20 Echo20 08/27/16 04:08:03 PM
#157607   So what's the next news we can expect! snayeman 08/27/16 01:32:48 PM
#157601   Sure why the heck not? scottsmith 08/27/16 07:50:39 AM
#157600   Scottsmith With testing being completed interest from big medicine Echo20 08/27/16 07:36:22 AM
#157599   It's clear Dr. Bertolino gave Leo an ultimatum: scottsmith 08/26/16 09:22:05 PM
#157598   How's this???, as one who has conversed with cascott 08/26/16 08:20:55 PM
#157597   Dr B is the man running things. Don't Rdunn88 08/26/16 07:06:48 PM
#157596   FINRA short sales of CTIX AlanC 08/26/16 07:02:52 PM
#157594   FINRA short sales of CTIX.... loanranger 08/26/16 04:33:13 PM
#157592   I read between the lines for these inside scottsmith 08/26/16 04:29:34 PM
#157591   Were you there when he said that? (I keltoi 08/26/16 04:03:57 PM
#157590   Dr. B told Leo "enough with the private scottsmith 08/26/16 03:53:28 PM
#157589   runninggirl2016 aware of Leo's reluctance to respond recently, JTORENCE 08/26/16 03:26:46 PM
#157588   Yes, I think all adverse events during the sox040713 08/26/16 03:21:21 PM
#157587   Correct. Endoscopic evaluation (+/-3 days after the final sox040713 08/26/16 03:19:13 PM
#157586   I'm not sure Leo is responding these days. runninggirl2016 08/26/16 02:52:11 PM
#157585   Does anyone have Leo's e-mail address, as I JTORENCE 08/26/16 02:50:34 PM
#157583   Sox this week is 7 weeks... runninggirl2016 08/26/16 02:02:26 PM
#157582   The treatment is six weeks long, so the sox040713 08/26/16 12:58:25 PM
#157581   Aren't SAE's sometimes found to be non drug-related? Darwinian 08/26/16 12:49:07 PM
#157579   The answer is no. From the interview with sox040713 08/26/16 12:42:03 PM
#157578   Luxe Levity: But they could buy it and divide it Echo20 08/26/16 12:31:13 PM
#157577   Geesh! I think I got it firgured JUST 10-11-12 08/26/16 12:05:31 PM
#157576   Nonsense trades for sure.. Citrati 08/26/16 12:04:02 PM
#157575   Figure it out.It is pretty obvious. keltoi 08/26/16 11:51:18 AM
#157574   Now why would KKR be interested in Cellceutix? luxe 08/26/16 11:43:20 AM
#157573   who are you responding too JUST 10-11-12 08/26/16 11:18:30 AM
#157572   I had a small Psoriasis spot on my luxe 08/26/16 10:54:38 AM
#157571   they probably didn't make it MXAMDUD 08/26/16 10:53:52 AM
#157570   Why haven't we received an update on the JTORENCE 08/26/16 10:46:47 AM
#157569   Boom! :-) thefamilyman 08/26/16 10:31:52 AM
#157568   No I did not recall the non compliance To infinity and beyond! 08/26/16 10:24:36 AM
#157566   To infinity and beyond georgejjl 08/26/16 10:16:00 AM
#157565   exit at 1.39? good nickel profit! vip1999 08/26/16 10:12:00 AM
#157564   Levity: Khol Kravis Roberts could be interested in CTIX... Echo20 Echo20 08/26/16 10:11:22 AM
#157563   bought some more at 1.34 MXAMDUD 08/26/16 10:10:29 AM
#157562   of course cannot have that allele- we have To infinity and beyond! 08/26/16 10:09:16 AM
#157560   Prurisol's potential sales should exceed over $2 BILLION georgejjl 08/26/16 09:58:21 AM
#157559   Cellceutix is extremely proud of the Phase 2 georgejjl 08/26/16 09:55:52 AM
#157557   Slip sliding away, slip sliding awaaaayyyyy MXAMDUD 08/26/16 09:47:30 AM
#157556   Yes, it is. georgejjl 08/26/16 09:40:08 AM
#157555   No it's not. scottsmith 08/26/16 09:23:18 AM
#157554   Prurisol is going to be a barn burner! JUST 10-11-12 08/26/16 09:19:09 AM
#157553   Prurisol as a potential treatment for prostate cancer, georgejjl 08/26/16 09:18:17 AM
#157552   Interesting regarding Prurisol and its global market georgejjl 08/26/16 08:48:09 AM
#157551   Prurisol as a potential treatment for rheumatoid arthritis georgejjl 08/26/16 08:39:15 AM
#157550   Global Prevalence of Psoriasis georgejjl 08/26/16 08:27:29 AM
#157549   Approximately 125 Million People Worldwide With Psoriasis georgejjl 08/26/16 08:17:13 AM